Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Cardiologists reveal the unexpected symptoms of clogged arteries and underlying heart disease that you should know about. The ...

Goldman Sachs initiated coverage on Silence Therapeutics (NASDAQ:SLN), currently trading at $4.92 with a market cap of $232.3 million, with a Sell rating and a price target of $6.00. According to ...

Uncertainty regarding the effectiveness and safety of intensive low-density lipoprotein cholesterol (LDL-C) reduction in ...

A research team revealed that insulin-like growth factor-binding protein 6 (IGFBP6) serves as a potential therapeutic target ...

A research team led by Prof. WENG Jianping from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences (CAS) revealed that insulin-like growth factor-binding ...

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...

Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.

Anderson, M.D., from the University of Pittsburgh, characterized national trends in preventive aspirin use (primary and secondary prevention) among populations at low and high ASCVD risk and with ...

View Full Profile. Learn about our Editorial Policies. The genetic predisposition to atherosclerotic cardiovascular disease (ASCVD) constitutes half of the known risk. Specific genetic variations, ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

“This has been shown pretty well in psoriasis with an association of atherosclerotic disease (ASCVD). So, in this study, we sought to elucidate a potential association with ASCVD and cutaneous ...